Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

FDA Rare Disease Shift 2026; New Regulatory Risks Pharma Teams Must Track

The U.S. Food and Drug Administration (FDA) is facing growing attention over how it evaluates Rare Disease Therapies in 2026. Discussions around FDA Advisory Committees (AdComms) and patient-focused decision-making highlight a broader regulatory transformation that may reshape how pharmaceutical companies
  • News
FDA Rare Disease Shift 2026; New Regulatory Risks Pharma Teams Must Track

One Leadership Change, Hidden GMP Risks; Why Quality Systems Start to Fail

Leadership experts in the healthcare sector have warned that organizational strategies often become vulnerable during executive transitions when they rely on individual leaders instead of institutional governance. Although the discussion originated from healthcare leadership, its implications extend directly to Pharmaceutical
  • News
One Leadership Change, Hidden GMP Risks; Why Quality Systems Start to Fail

FDA Approves Subcutaneous Isatuximab; Why PK Bridging May Redefine Future Biologic Approvals

The U.S. Food and Drug Administration (FDA) has approved the subcutaneous formulation of isatuximab-irfc (Sarclisa Escena) for three multiple myeloma treatment regimens, expanding an anti-CD38 therapy that was previously available only as an intravenous infusion. While the approval offers patients
  • News
FDA Approves Subcutaneous Isatuximab; Why PK Bridging May Redefine Future Biologic Approvals

FDA Freezes CRL Transparency; What Changes for Pharma Compliance

The FDA has paused the public release of new Complete Response Letters (CRLs) while reviewing a citizen petition that challenges the legal basis of the disclosure program. The decision temporarily interrupts one of the agency’s most significant transparency initiatives and
  • News
FDA Freezes CRL Transparency; What Changes for Pharma Compliance

MindRank Secures $52M; AI-Designed Drugs Move Beyond Discovery

Artificial intelligence has taken another step from research into regulated drug development. Chinese biotech MindRank has secured $52 million in Series B funding to advance its AI-powered drug discovery platform and accelerate the clinical development of its oral GLP-1 receptor
  • News
MindRank Secures $52M; AI-Designed Drugs Move Beyond Discovery

FDA Speeds Up IND Reviews; Experts Say Protocol Design Still Drives Success

The U.S. Department of Health and Human Services (HHS) has introduced Operation Trialblazer, a multi-agency initiative designed to accelerate early-stage drug development and modernize clinical research across the United States. Working alongside the FDA and the National Institutes of Health
  • News
FDA Speeds Up IND Reviews; Experts Say Protocol Design Still Drives Success

FDA Transparency Hits a Roadblock; Why Drug Rejection Letters Suddenly Stopped

The U.S. Food and Drug Administration (FDA) has temporarily paused the public release of Complete Response Letters (CRLs). The agency made the decision after an unnamed pharmaceutical company challenged the policy over confidentiality concerns. The move temporarily suspends one of
  • News
FDA Transparency Hits a Roadblock; Why Drug Rejection Letters Suddenly Stopped

China Drives Pharma Innovation; Regulatory Scrutiny Is Rising Alongside It

AstraZeneca and GSK have announced separate agreements with China's Sino Biopharm, reinforcing a growing trend of cross-border pharmaceutical partnerships. AstraZeneca licensed an investigational respiratory medicine, while GSK expanded its commercial collaboration in China. The announcements come as regulators increasingly examine
  • News
China Drives Pharma Innovation; Regulatory Scrutiny Is Rising Alongside It

ConcertAI Expands CancerLinQ; Trust in Clinical AI Now Depends on Validation

ConcertAI has expanded its CancerLinQ platform beyond quality reporting into an AI-powered clinical decision support system that integrates trial matching, structured data extraction, and real-time oncology insights. The announcement highlights a broader industry shift: as AI becomes part of clinical
  • News
ConcertAI Expands CancerLinQ; Trust in Clinical AI Now Depends on Validation

EMA Launches Phased Reviews; Why GMP Submission Strategies Must Change

The European Medicines Agency (EMA) has started a phased review of daraxonrasib, an investigational therapy for metastatic pancreatic cancer. However, the biggest story is not the medicine itself. Instead, the review marks one of the first real-world applications of a
  • News
EMA Launches Phased Reviews; Why GMP Submission Strategies Must Change